Tags
Cartilage Repair
Specialties
Regenerative Medicine
36 results found in 4ms
What ChondroFiller's CE approval means for UK patientsWhat ChondroFiller's CE approval means for UK patients
ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
What the ChondroFiller evidence actually showsWhat the ChondroFiller evidence actually shows
ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
Finding a ChondroFiller specialist in the UKFinding a ChondroFiller specialist in the UK
ChondroFiller provision is concentrated in London specialist centres because its Class III medical device status requires prescription import from Germany, real-time ultrasound-guided placement, and specialist MRI assessment to determine patient suitability.ChondroFiller provision is concentrated in London specialist centres because its Class III medical device status requires prescription import from Germany, real-time ultrasound-guided placement, and specialist MRI assessment to determine patient suitability.
Is ChondroFiller available on the NHSIs ChondroFiller available on the NHS
ChondroFiller is not available on the NHS anywhere in the UK; patients must access this collagen cartilage scaffold privately, with single injections typically costing around £3,000.ChondroFiller is not available on the NHS anywhere in the UK; patients must access this collagen cartilage scaffold privately, with single injections typically costing around £3,000.
Who qualifies for a ChondroFiller injectionWho qualifies for a ChondroFiller injection
ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
Questions that reveal ChondroFiller provider expertiseQuestions that reveal ChondroFiller provider expertise
ChondroFiller triggers cartilage repair through a structural scaffold—unlike hyaluronic acid, which lubricates, or corticosteroids, which reduce inflammation. The UK competency gap is wider than for standard injections; correct patient selection demands imaging knowledge and clinical precision.ChondroFiller triggers cartilage repair through a structural scaffold—unlike hyaluronic acid, which lubricates, or corticosteroids, which reduce inflammation. The UK competency gap is wider than for standard injections; correct patient selection demands imaging knowledge and clinical precision.
ChondroFiller IKDC and MOCART scoresChondroFiller IKDC and MOCART scores
ChondroFiller patients' functional-outcome scores (IKDC) gain approximately 30 points within 12 months, rising from ~48 to ~80, whilst structural MRI (MOCART) markers advance from 65 to 81–84 — dual tracks converging on tissue repair and restored joint function.ChondroFiller patients' functional-outcome scores (IKDC) gain approximately 30 points within 12 months, rising from ~48 to ~80, whilst structural MRI (MOCART) markers advance from 65 to 81–84 — dual tracks converging on tissue repair and restored joint function.
Why ChondroFiller requires a specialist injection pathwayWhy ChondroFiller requires a specialist injection pathway
ChondroFiller, a collagen matrix, self-polymerises within three to five minutes of injection; needle placement under ultrasound guidance must therefore be exact, as repositioning becomes impossible once gelation begins and structural repair unfolds over six to twelve months.ChondroFiller, a collagen matrix, self-polymerises within three to five minutes of injection; needle placement under ultrasound guidance must therefore be exact, as repositioning becomes impossible once gelation begins and structural repair unfolds over six to twelve months.
ChondroFiller injection vs surgery for focal knee cartilageChondroFiller injection vs surgery for focal knee cartilage
An ultrasound-guided collagen injection activates the joint's own regenerative cells to repair focal knee cartilage defects; 70–85% of treated patients report meaningful symptom relief within three to five years.An ultrasound-guided collagen injection activates the joint's own regenerative cells to repair focal knee cartilage defects; 70–85% of treated patients report meaningful symptom relief within three to five years.
How long ChondroFiller results lastHow long ChondroFiller results last
ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.
ChondroFiller vs PRP for focal cartilage defectsChondroFiller vs PRP for focal cartilage defects
Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlyingFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
ChondroFiller or Arthrosamid for your kneeChondroFiller or Arthrosamid for your knee
ChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.ChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.
36 results found in 4ms